Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
Uber to Acquire Delivery Hero in $14.8 Billion Deal to Expand Global Food Delivery Business 
Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
NEW YORK, Feb. 01, 2016 -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Leerink Partners’ 5th Annual Global Healthcare Conference in New York. The presentation is scheduled for Wednesday, February 10th, 2016 at 8:50 am EST.
The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
About Intra-Cellular Therapies
Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in dementia, depression and other neuropsychiatric and neurological disorders. ITI-007, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia and bipolar depression. The Company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders.
Contact: Juan Sanchez, M.D. Vice President Corporate Communications and Investor Relations of Intra-Cellular Therapies, Inc. Phone: 212-923-3344 Burns McClellan, Inc. Lisa Burns Justin Jackson (Media) [email protected] 212-213-0006
